Lifeward Ltd. (LFWD): M&A transaction — Lifeward completes acquisition of Oratech Pharma, issues shares and convertible notes

Lifeward Ltd.

Lifeward completed acquisition of Oratech Pharma on March 25, 2026, issuing 2,256,476 ordinary shares and pre-funded warrants to Oramed.
Issued $10,000,000 aggregate principal amount of senior secured convertible notes and warrants in a private placement.
Directors Dr. John William Poduska and Randel Richner resigned effective March 25, 2026.
Appointed Nadav Kidron, Miriam Kidron, and Yehuda Reznick as new directors, expanding board from five to eight.
Entered into a First Amendment and Assignment to assign Oratech Pharma rights to Oratech Ltd.

item 2.01 item 1.01 item 3.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Lifeward Ltd. issued convertible note to Oramed and certain investors for $10,000,000.00 aggregate principal amount.

Security: convertible note
Purchaser: Oramed and certain investors
Consideration: $10,000,000.00 aggregate principal amount

Exact text from the filing

On March 25, 2026, the Company issued: (i) $10,000,000.00 aggregate principal amount senior secured convertible notes (the “Initial Notes”), convertible into Ordinary Shares, and (ii) accompanying warrants to purchase Ordinary Shares (the “Initial Warrants”).

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Lifeward Ltd. issued warrant to Oramed and certain investors.

Security: warrant
Purchaser: Oramed and certain investors

Exact text from the filing

On March 25, 2026, the Company issued: (i) $10,000,000.00 aggregate principal amount senior secured convertible notes (the “Initial Notes”), convertible into Ordinary Shares, and (ii) accompanying warrants to purchase Ordinary Shares (the “Initial Warrants”).

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Lifeward Ltd. completed an acquisition involving Oramed Pharmaceuticals, Inc. (closed 2026-03-25).

Action: acquisition
Counterparty: Oramed Pharmaceuticals, Inc.
Closing: 2026-03-25

Exact text from the filing

On March 25, 2026, the Company completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.

View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Lifeward Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-26-001724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.